Therefore, it is tempting to assume that an appropriate upregulation of cardiac, pulmonary and renal ACE2, along enhanced Ang 1‐7 production may represent an advantageous compensatory response in compensated CHF facing SARS‐CoV‐2 infection, whereas failure of ACE2 upregulation in decompensated CHF may contribute to the pathogenesis of heart failure and aggravates their COVID‐19 manifestations due to the lack of adequate Ang 1‐7 production. Here, ACE2 is linked to congestive heart failure.